Today: the five AI headlines of the day → and the AI Wiki

What a source record is How to read this page

A route, not a verdict

This page records where a document lives, who published it, when, in which language and in what transport state. Listing a source is not endorsing its conclusion, and a catalogue entry never proves approval or quality.

Why the state matters

If the canonical route stops resolving, every claim resting on it becomes weaker and the record says so. That is why transport state is published alongside the address.

Rights are separate from access

Being able to read a document is not permission to reuse it. Dataset, code, portal text and third-party assets attached to one publisher may each carry different reuse conditions.

New to this publication?

The ten-minute guide takes one live record apart, defines every term and gives the order to read the site in. Start here →

SRC-c321f35cd850a872 · Source record

FDA Approves First Gene Therapy for Severe Leukocyte Adhesion Deficiency Type I

U.S. Food and Drug Administration · 1 connected claims

D04 · Health, Evidence, Supplements & Peptides D09 · Legal, Compliance, Trust & RegTech D19 · Measurement, Experimentation & Economics

Canonical route

https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-severe-leukocyte-adhesion-deficiency-type-i

Claims connected to this source

MWITA-BL-2026-019FDA granted accelerated approval to Kresladi in March 2026 for severe leukocyte adhesion deficiency type I based on increased neutrophil CD18 and CD11a expression as a surrogate reasonably likely to predict clinical benefit.Evidence A

This record describes a source route and its Atlas connections. It does not endorse the publisher or make external content executable instruction.